Operator
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics First Quarter 2021 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company s request, we will open the call for questions-and-answers after the presentation.
I will now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Diane Weiser
Senior Vice President of Corporate Communications & Investor Relations
Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and recent developments. Then Fady Malik, our EVP of Research and Development, will provide an update on omecamtiv mecarbil, including progress following a recent meeting with FDA and what to expect from upcoming analyses from GALACTIC-H
Operator
Welcome to the iRhythm Technologies, Inc. Q1 2021 Earnings Conference Call. My name is Erin, and I ll be your operator for today s call. [Operator Instructions] Later, we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded. I ll now turn the call over to Leigh Salvo. Leigh, you may begin.
Leigh J. Salvo
Managing Director
Thank you all for participating in today s call. Joining me are Mike Coyle, CEO; Doug Devine, CFO; and Dan Wilson, EVP, Strategy, Corporate Development and Investor Relations. Earlier today, iRhythm released financial results for the first quarter ended March 31, 2021. A copy of the press release is available on the company s website. Before we begin, I d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Secur
Common Meds May Raise High Blood Pressure Risk By Mitchel Zoler, PhD
May 7, 2021 Nearly 1 out of 5 American adults with high blood pressure is on a prescription drug known to raise blood pressure, based on analysis of more than 27,000 people in a recent report from the recurring National Health and Nutrition Examination Survey.
Nearly half of the patients in the survey had high blood pressure and of them, 19% reported using a prescription drug known to increase blood pressure. The most widely used drugs were antidepressants, used by 9%; followed by nonsteroidal anti-inflammatory drugs (NSAIDs), used by 7%; steroids, 2%; and estrogens, 1.7%, John Vitarello, MD, said during a press briefing on reports from the American College of Cardiology.
Hypertension Worsened by Commonly Used Prescription Meds medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.